Slide 1: 2016 AGM Presentation
For personal use only 2016 AGM PRESENTATION November 2016
Slide 2: Forward-Looking Statement
Forward-Looking Statement For personal use only Certain statements made in this presentation are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guida
Slide 3: FY2016: Setting Up for Transformational CY2017
FY2016 Setting Up for Transformational CY2017 For personal use only FY2016 Strong execution of priority pipeline programs (NASH Phase II, C. Difficile, Travelan, & Other New Programs) through the strategic use of capital resources has placed Immuron in strong position to achieve major inflection mil
Slide 4: Key Events of 2016 Significantly Strengthened our Value Proposition
FY2016 Key Events of 2016 Significantly Strengthened our Value Proposition For personal use only Key Events 2016 Immuron’s Value Proposition 1• Acceleration of NASH Phase II • Confirmed the validity, versatility and Recruitment long-term potential of our proprietary platform 2• World-class results f
Slide 5: NASH Recruiting: Changes to Trial Reset the Recruiting Curve
1 NASH Recruiting Changes to Trial Reset the Recruiting Curve For personal use only Cumulative Randomization Drivers 120 • Amendment initiated in May 2016 significantly 104 sped up recruiting by 100 removing barriers to Major Amendment to 95 recruiting including 89 Phase II clinical trial changes to
Slide 6: C. difficile Results
2 C. difficile Results Confirmed Strength and Potential of Anti-Infective Platform For personal use only Relapse: ~90% survival in IMM-529 + vancomycin group (n=7/9); vs. 11% survival in the control group which received vancomycin alone (n=1/9) Prevention of C. difficile Infection: ~70% (17/24) surv
Slide 7: IMM-529: Unique Triple-Action MOA in CDI
2 IMM-529 Unique Triple-Action MOA in CDI For personal use only Spores – Infectious Particles IMM-529 antibodies bind to Heat, ethanol & UV surface antigens on spores resistant. Survive gastric & prevent adheres to host acid, adhere to cells in the cells & limit germination. colon & germinate Vegeta
Slide 8: Expanding Pipeline
3 Expanding Pipeline Expansion of Trials at Minimal Costs to Shareholders For personal use only Dosing Development Status Program MOA Indication Notes Form Pre-Clinical Phase 1 Phase 2 Phase 3 IMM-124E Anti-LPS Oral NASH Top line results in mid-2017 IMM-124E Anti-LPS Oral ASH NIH Funded; UVA 1 IMM-1
Slide 9: Travelan Growth Continues
4 Travelan Growth Continues WW Growth For personal use only • FY2016 Sales total $1.2M (up 3% from FY2015) • July 2016 – October 2016, sales are outpacing last year’s sales (same period) - New marketing strategies developed for Australia and the US. Added marketing team with mixed skills set (tradit
Slide 10: Corporate Activities: Rights Issue and NASDAQ Listing
5 Corporate Activities Rights Issue and NASDAQ Listing For personal use only • Secured needed funding to support all key activities including finalizing NASH recruitment, conducting NASH interim results, and June 2016 continue investing in Travelan and C. difficile Rights Issue • Strong NASH LM&A ac
Slide 11: Attractive LM&A Activities
6 Attractive LM&A Activities Big Pharma Will Continue to Drive Active LM&A Market For personal use only • (2010) Acquired Arresto for US$225m + potential for future payments. Phase I asset (LoxL2 antibody) targeting NASH, IPF • (2012) Regulus: Preclinical. AZN paid US$125m per compound including dev
Slide 12: NASH Is a Huge Opportunity
6 NASH Is a Huge Opportunity LM&A Market Driven by Disease Epidemiology and Lack of Treat For personal use only NASH: The most severe form of liver injury in the spectrum of non- alcoholic fatty liver disease (NAFLD) Market Estimated to top $35B-$40B WW by 2030 driven by Size obesity epidemic (Deutc
Slide 13: IMM-124E Value Proposition
6 IMM-124E Value Proposition Asset with Broadest Potential Use For personal use only NASH Cirrhosis NAFLD 25M People 1.2M people Up to 145M People F0 F1 F2 F3 F4 17M people F1+F2+F3 = 8M people NAFLD • No regulatory pathway currently exists for NAFLD Intercept (OCA) • Drug would need to be Tobira (C
Slide 14: Share Performance
July 1 2015 to 25 Nov 2016 Share Performance For personal use only Share Price Performance: 1 July 2015 to 25 Nov 2016 Travelan US Sales C-Diff Pre- US OTCQB Partnerships Signed Clinical Results Listing NASH Update US CVS and McKesson 100 Patients Travelan Partnerships Rights Issue Closed Over-subsc
Slide 15: Key Milestones
Key Milestones Near-Term and Medium-Term Milestones For personal use only Major Milestones Timing OTC Products - Continued Expansion (New Territory and Sales Growth) Ongoing NASH Phase II - 120 Patients Randomized Dec 2016/Jan 2017 NASDAQ Listing and US Capital Raise 1Q2017 NASH Phase II - Interim R
Slide 16: Summary
Summary FY2016 Efforts Are Positioning Immuron for Successful FY2017 For personal use only Major Company Inflexion Points + Demand for NASH Assets + Potentially Transformative FY2017 Completion of NASH Phase II Recruitment NASH Phase II Interim Analysis NASH Phase II Results NASDAQ Listing/ Access t
Slide 17: Thank You
For personal use only THANK YOU